Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
If approved it will bring a second source of MMR vaccine to the US market
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Company working on COVID vaccine INO 4800
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Filing for WHO Emergency Use Authorisation this month
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
Five seats reserved for Wards of COVID warriors in central MBBS admission
It works as an adjunct to standard care based on robust clinical trials
Subscribe To Our Newsletter & Stay Updated
